{
  "meta": {
    "title": "43_National_Tb_Elimination_Program_Ntep",
    "url": "https://brainandscalpel.vercel.app/43-national-tb-elimination-program-ntep-04a8c823.html",
    "scrapedAt": "2025-11-30T18:15:12.497Z"
  },
  "questions": [
    {
      "text": "How many weight band categories are present in the Daily Drug Regimen (DDR) for the treatment of tuberculosis in adults?",
      "choices": [
        {
          "id": 0,
          "text": "Five"
        },
        {
          "id": 1,
          "text": "Six"
        },
        {
          "id": 2,
          "text": "Three"
        },
        {
          "id": 3,
          "text": "Four"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct Answer: A) Five </strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<ul>\n\t<li>The adult <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">tuberculosis</span> protocols often categorize patients into weight bands to adjust medication dosages appropriately.</li>\n\t<li>There are <strong>5 weight band</strong> <strong>categories</strong> present in the treatment of<strong> adult TB. </strong></li>\n\t<li>Advantages of weight bands:</li>\n</ul>\n\n<p>Increased compliance</p>\n\n<p>Decrease the chance of <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">Drug-resistant</span> TB</p>\n\n<p> </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:576px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Weight category (kg)</strong></p>\n\t\t\t</td>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Number of tablets (FDCs)</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Intensive phase- 4 FDC (HRZE)- 75/100/400/275</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Continuation phase- 3 FDC (HRE)- 75/150/275</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>25-34</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>35-49</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>60-64</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>65-75</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>5</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>5</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>>75*</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>6</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>6</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"3\" rowspan=\"2\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Note: Patients >75 kg may receive five tablets per day if they do not tolerate the revised dose.</p>\n\n\t\t\t<ul>\n\t\t\t\t<li>Total doses taken in the <span class=\"customMeta\" data-dictid=\"901bf573f216927771905f0abedca2\">Intensive</span> phase (IP) is 56 doses.</li>\n\t\t\t\t<li>Total doses taken in the Continuation phase (CP) is 112 doses.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p><strong>6 weight bands</strong> are used to manage <strong>pediatric TB </strong>but not adult TB. <strong>(Option B)</strong></p>\n\n<p><br />\n </p>\n\n<p>HRZ is given as FDC, and Ethambutol is given as a separate tablet.</p>\n\n<p> </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:NaN\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td rowspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Weight category (kg)</strong></p>\n\t\t\t</td>\n\t\t\t<td colspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Number of tablets (dispersibe FDCs)</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Intensive phase</strong></p>\n\t\t\t</td>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Continuation phase</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>HRZ</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>E</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>HR</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>E</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>50/75/150</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>100</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>50/75</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>100</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4-7</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>1</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>1</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>1</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>1</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>8-11</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>12-15</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>16-24</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>25-29</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3 + 1A*</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3 + 1A*</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>30-39</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2 + 2A*</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2 + 2A*</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p>*A=Adult FDC (HRZE = 75/150/400/275; HRE = 75/150/275). It is added in higher weight band categories i.e., > 25 kg as these children may be able to swallow tablets</p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/MTB1968N0J4z8aCvT1P21747246961.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/J7KhWPvfg3Yx4Nq0eXKO1747247021.mp3"
    },
    {
      "text": "According to the NTEP guidelines, what population size does each Tuberculosis Unit (TU) cover?",
      "choices": [
        {
          "id": 0,
          "text": "1 per 50,000 in rural/urban areas and 1 per 25,000 in hilly/tribal areas"
        },
        {
          "id": 1,
          "text": "1 per 100,000 in rural/urban areas and 1 per 50,000 in hilly/tribal areas"
        },
        {
          "id": 2,
          "text": "1 per 200,000 in rural/urban areas and 1 per 100,000 in hilly/tribal areas"
        },
        {
          "id": 3,
          "text": "1 per 300,000 in rural/urban areas and 1 per 150,000 in hilly/tribal areas"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C)</strong> <strong>1 per 200,000 in rural/urban areas and 1 per 100,000 in hilly/tribal areas</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>TB Unit:</strong></p>\n\n<ul>\n\t<li>The TU is the nodal point for TB control activities in the sub-district- at CHC level</li>\n\t<li>Covers a population of 200,000 (1.5 – 2.5 lakh) in urban/rural areas and 100,000 (0.75 – 1.25 lakh) in hilly/tribal/difficult areas.</li>\n\t<li>Each TU includes a Medical Officer-TB Control (MO-TC) and a Senior Treatment Supervisor (STS). Extra staff are provided based on TB case load.</li>\n\t<li>Each TU has a Designated <span class=\"customMeta\" data-dictid=\"51df8cdfc91692777192aa76f4de51\">Microscopy</span> <span class=\"customMeta\" data-dictid=\"1feb2a0a3016927771847db9449f75\">Centre</span> (DMC)( most <span class=\"customMeta\" data-dictid=\"255674f3271692777195c172d86daf\">peripheral</span> unit to diagnose Tb) for every 50,000 - 100,000 population, expanding to PHCs and various hospitals for wider coverage.</li>\n</ul>\n\n<p><strong>Organizational/ Structural Setup: </strong></p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"588\" src=\"https://image.prepladder.com/content/Xhtk2887qRBFZzRmf5sm1734267734.png\" width=\"500\" /></p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/Xhtk2887qRBFZzRmf5sm1734267734.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/cWBRvnDUKZ37KUDeDpEj1747246517.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/aGeZyc3q5hbdhB2TLNZc1748206801.mp3"
    },
    {
      "text": "Which initiative in India focuses on supporting District Drug Resistant TB Centres (DDR -TC) in management of drug-resistant tuberculosis (TB)?",
      "choices": [
        {
          "id": 0,
          "text": "Indian TB Genomic Surveillance Consortium"
        },
        {
          "id": 1,
          "text": "DT3 Centers"
        },
        {
          "id": 2,
          "text": "Dare2eraD TB (2022)"
        },
        {
          "id": 3,
          "text": "TRACE-TB Project"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) DT3 Centers</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>DT3C - Difficult to Treat TB Centers</strong>, are specialized facilities at State/National level - established under the NTEP in India.</p>\n\n<ul>\n\t<li>Initiative to support District and Nodal <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">Drug-resistant</span> TB Centres (DR-TBCs) for effective management of <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">Drug-resistant</span> TB (DR-TB) cases.</li>\n\t<li>The DR-TBC shares patient queries in a standardized format ahead of time to enable discussion through state nodal officer.</li>\n\t<li>The primary goal of D3T centers is to improve treatment outcomes for challenging TB cases and to reduce the spread of <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">drug-resistant</span> TB within communities.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>\"Dare2eraD TB\" - Data-Driven Research to Eradicate TB (Option C):</strong> It is an umbrella program introduced by the Department of <span class=\"customMeta\" data-dictid=\"177a32fb7f1692777183fcc83ba413\">Biotechnology</span> (DBT) on World TB Day, March 24, 2022.</p>\n\n<p>It comprises following initiatives:</p>\n\n<ul>\n\t<li><strong>Indian <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">Tuberculosis</span> Genomic Surveillance Consortium - InTGS (Option A)</strong>\n\n\t<ul>\n\t\t<li>To track genomic variations in M. <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">tuberculosis</span> across a network of multiple laboratories.</li>\n\t</ul>\n\t</li>\n\t<li>Indian TB Knowledge Hub- Webinar Series - InTBK Hub</li>\n\t<li>Researching therapies that target host responses against TB and establishing an <span class=\"customMeta\" data-dictid=\"a9dcc16be01692777187410eac8a4a\">evidence-based</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> for treating extra-pulmonary tuberculosis.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>TRACE-TB Project</strong> <strong>(Option D):</strong> \"Transformative Research and <span class=\"customMeta\" data-dictid=\"56c694c63b1692777182bd67477b65\">Artificial Intelligence</span> Capacity for <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">Elimination</span> of TB and Responding to <span class=\"customMeta\" data-dictid=\"aa279cf1f016927771903f195bb1b9\">Infectious</span> Diseases.\"</p>\n\n<ul>\n\t<li>It is an initiative aimed at utilizing <span class=\"customMeta\" data-dictid=\"56c694c63b1692777182bd67477b65\">artificial intelligence</span> and transformative research to improve the detection, treatment, and management of <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">tuberculosis</span> (TB) and other <span class=\"customMeta\" data-dictid=\"aa279cf1f016927771903f195bb1b9\">infectious</span> diseases.</li>\n\t<li>Done by Wadhwani AI in partnership with USAID to support the NTEP.</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/fn2xxYTkR65PN8K1YL5F1743280132.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/pckyeXPNBEqnBTZb07pL1743280217.mp3"
    },
    {
      "text": "When is World Tuberculosis (TB) Day observed, and what is the theme for 2024?",
      "choices": [
        {
          "id": 0,
          "text": "March 24; \"Invest to End TB. Save Lives.\""
        },
        {
          "id": 1,
          "text": "March 24; \"Yes! We Can End TB.\""
        },
        {
          "id": 2,
          "text": "April 24; \"The Clock is Ticking.\""
        },
        {
          "id": 3,
          "text": "April 24; \"Unite to End TB.\""
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) March 24; \"Yes! We Can End TB.\"</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>World <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">Tuberculosis</span> (TB) Day</strong></p>\n\n<ul>\n\t<li><strong>Date: </strong>March 24th of every year</li>\n\t<li><strong>Theme for 2024: </strong>\"Yes! We can end TB.\"</li>\n\t<li><strong>Purpose: </strong>\n\t<ul>\n\t\t<li>World TB Day raises awareness about <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">tuberculosis</span> globally.</li>\n\t\t<li>It highlights progress in prevention, treatment, and control efforts while advocating for continued action to eliminate TB worldwide.</li>\n\t\t<li>The theme underscores the importance of <span class=\"customMeta\" data-dictid=\"73b3d4c73416927771905a7b0fab77\">investing</span> in research, healthcare infrastructure, and <span class=\"customMeta\" data-dictid=\"f42f73407916927771969cb688f953\">public health</span> strategies to achieve the goal of <span class=\"customMeta\" data-dictid=\"7ae760ae1b169277718794068316b8\">ending</span> TB as a <span class=\"customMeta\" data-dictid=\"f42f73407916927771969cb688f953\">public health</span> threat.</li>\n\t</ul>\n\t</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/1P44KGcvjmiNpNxpNWnG1743280259.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/3DUZVax744crhvaGdN811743280303.mp3"
    },
    {
      "text": "Which technology-based initiative has been implemented by the Indian government to track and manage tuberculosis (TB) cases?",
      "choices": [
        {
          "id": 0,
          "text": "Swasthya Sathi"
        },
        {
          "id": 1,
          "text": "eVIN"
        },
        {
          "id": 2,
          "text": "Nikshay"
        },
        {
          "id": 3,
          "text": "Aarogya Setu"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Nikshay </strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>Nikshay is the technology based initiative launched by GoI to track and manage TB cases.</p>\n\n<p><strong>NI-KSHAY (Ni=End, Kshay=TB):</strong></p>\n\n<ul>\n\t<li>Web-based TB patient management system under the National <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">Tuberculosis</span> <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">Elimination</span> Programme (NTEP).</li>\n\t<li>Used to register TB cases, order lab tests, record treatment details, monitor treatment adherence, transfer cases between providers.</li>\n\t<li>Acts as the National TB Surveillance System, reporting data to the government.</li>\n\t<li>Used by Health workers in both public and private sectors nationwide.</li>\n</ul>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"171\" src=\"https://image.prepladder.com/content/0i4SjOYtsuB6hbDOB0SL1725457951.png\" width=\"500\" /></p>\n\n<p><strong>Other Technology based initiatives for TB:</strong></p>\n\n<p><strong>TRUENAT:</strong> Rapid molecular <span class=\"customMeta\" data-dictid=\"552e9ef8811692777186997018b858\">diagnostic</span> tool developed locally</p>\n\n<p>This platform employs <span class=\"customMeta\" data-dictid=\"9ddd195e9a1692777197bb3f135c2e\">real-time</span> <span class=\"customMeta\" data-dictid=\"fa67319b42169277719498abc93db6\">PCR</span> integrated into micro-PCR chips</p>\n\n<ul>\n\t<li><strong>Truenat MTB and Truenat MTB Plus</strong> - detect <span class=\"customMeta\" data-dictid=\"e99dbef99f169277719344843cf75a\">Mycobacterium</span> <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">tuberculosis</span> bacteria for TB diagnosis</li>\n\t<li><strong>Truenat MTB-RIF Dx </strong>- identifies resistance to rifampicin.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>99DOTS: </strong></p>\n\n<ul>\n\t<li>A cost-effective method to monitor and improve <span class=\"customMeta\" data-dictid=\"5f8b7d103016927771806be7e4190b\">adherence</span> to TB medication.</li>\n\t<li>Anti-TB <span class=\"customMeta\" data-dictid=\"495ed15ced1692777183595fc14e52\">blister</span> packs are wrapped in envelopes with hidden toll free phone numbers revealed only when doses are dispensed.</li>\n\t<li>Patients make a call to the hidden number after taking their medication, confirming dose intake.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>MERM (Medication Event Reminder Monitor):</strong> An electronic device designed to enhance TB medication <span class=\"customMeta\" data-dictid=\"5f8b7d103016927771806be7e4190b\">adherence</span> by providing reminders and <span class=\"customMeta\" data-dictid=\"ebb0986d331692777200ab09e1b2e8\">tracking</span> medication intake.</p>\n\n<ul>\n\t<li>Reminders: Issues audio reminders to patients to take their TB medication.</li>\n\t<li>Monitoring: Records the date and time when the medication box is opened, allowing for accurate <span class=\"customMeta\" data-dictid=\"ebb0986d331692777200ab09e1b2e8\">tracking</span> of adherence.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Swasthya Sathi</strong> <strong>(Option A):</strong>Launched by the Chief Minister of West Bengal.</p>\n\n<ul>\n\t<li>Provides health coverage up to Rs. 5 lakh per family annually for secondary and <span class=\"customMeta\" data-dictid=\"22e8a6f65016927772003e97740ab2\">tertiary</span> care.</li>\n</ul>\n\n<div style=\"text-align:center\">\n<figure class=\"caption_element\" style=\"display:inline-block\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"500\" src=\"https://image.prepladder.com/content/LsGlWexPRkDDSyGUkwnz1725457967.png\" width=\"500\" />\n<figcaption>{{caption_text}}</figcaption>\n</figure>\n</div>\n\n<p>The <strong>eVIN (Electronic Vaccine Intelligence Network)</strong> <strong>(Option B)</strong> initiative is designed to deliver <span class=\"customMeta\" data-dictid=\"9ddd195e9a1692777197bb3f135c2e\">real-time</span> updates on vaccine inventory levels, distribution, and storage conditions across all cold chain locations within the country.</p>\n\n<div style=\"text-align:center\">\n<figure class=\"caption_element\" style=\"display:inline-block\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"190\" src=\"https://image.prepladder.com/content/JAwZwcBswyvvv1phbP1m1725447608.png\" width=\"500\" />\n<figcaption>{{caption_text}}</figcaption>\n</figure>\n</div>\n\n<p><strong>Aarogya Setu</strong> <strong>(Option D)</strong> is a mobile application developed by the GoI to track and <span class=\"customMeta\" data-dictid=\"a3b8e7d7ec1692777192646b2c8f69\">mitigate</span> the spread of <span class=\"customMeta\" data-dictid=\"2d364aeaf7169277718529fa58f6ea\">COVID-19</span> by providing users with information on their risk of infection based on their location and contact history.</p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"Ramu ummadishetty\" data-hash=\"\" data-license=\"CC BY-SA 4.0\" data-source=\"https://te.wikipedia.org/wiki/%E0%B0%86%E0%B0%B0%E0%B1%8B%E0%B0%97%E0%B1%8D%E0%B0%AF_%E0%B0%B8%E0%B1%87%E0%B0%A4%E0%B1%81#/media/%E0%B0%A6%E0%B0%B8%E0%B1%8D%E0%B0%A4%E0%B1%8D%E0%B0%B0%E0%B0%82:%E0%B0%86%E0%B0%B0%E0%B1%8B%E0%B0%97%E0%B1%8D%E0%B0%AF_%E0%B0%B8%E0%B1%87%E0%B0%A4%E0%B1%81_.jpg\" data-tags=\"\" height=\"857\" src=\"https://image.prepladder.com/content/GuaWAEOf5TrASoJp17fW1725457983.png\" width=\"500\" /></p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/0i4SjOYtsuB6hbDOB0SL1725457951.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/RC3EfSpClF1HqAgxAyGy1743280578.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/cAami0IJV4Et4cwYvh8A1743280655.mp3"
    },
    {
      "text": "What is the monthly financial incentive provided under the Nikshay Poshan Yojana for TB patients to support their nutritional needs?",
      "choices": [
        {
          "id": 0,
          "text": "Rs 300"
        },
        {
          "id": 1,
          "text": "Rs 500"
        },
        {
          "id": 2,
          "text": "Rs 750"
        },
        {
          "id": 3,
          "text": "Rs 1000"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) Rs 500</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The<strong> Nikshay Poshan Yojana</strong> is a scheme for TB patients by MoHFW, GOI</p>\n\n<ul>\n\t<li>Provides a monthly financial incentive of Rs 1000 to TB patients to support their nutritional needs during the course of their treatment.</li>\n\t<li>Patients from notified tribal areas are provided with one time incentive of Rs.750 for transport allowance.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Other incentives under TB:</strong></p>\n\n<p><strong>Private Practitioner/Hospital and Informants:</strong></p>\n\n<ul>\n\t<li>A one-time incentive of Rs. 500 upon notification, and</li>\n\t<li>An additional Rs. 500 for updating the treatment outcome to a private practitioner or hospital.</li>\n\t<li>Can notify a TB case up to 30 days.</li>\n\t<li>If fails to do so, it is a punishable offense under IPC 269 & 270. Fine: Rs. 10000 &/or imprisonment for 6 months.</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Community Treatment Supporters:</strong></p>\n\n<ul>\n\t<li>Rs.1000 one time incentive on treatment completion of Drug sensitive TB patient.</li>\n\t<li>Rs. 2000 at the end of IP and Rs.3000 at the end of CP of Drug resistant TB patients (Total Rs.5000).</li>\n\t<li>Any person from the community, who helps in detecting a <span class=\"customMeta\" data-dictid=\"cced7d91ec169277719680ab298ccf\">presumptive</span> TB case, will get an incentive of Rs.500.</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/FyGkg0eBCZ5udNm1bIKA1743280752.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/81nRNVB9bIWw24rWGUer1743280835.mp3"
    },
    {
      "text": "You diagnose a 35 year old man with tuberculosis. Further questioning his social history reveals that he lives with his elderly parents and wife in a seemingly small apartment. Which of the following would you recommend as prophylactic treatment for his family members?",
      "choices": [
        {
          "id": 0,
          "text": "Isoniazid (600mg OD) for 6 months"
        },
        {
          "id": 1,
          "text": "Shorter TPT (TB Preventive Therapy) - Rifapentine + Isoniazid weekly for 3 months"
        },
        {
          "id": 2,
          "text": "Pyrizinamide (800mg OD) for 3 months."
        },
        {
          "id": 3,
          "text": "Rifampicin (1500mg OD) for 9 months."
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) Shorter TPT (TB <span class=\"customMeta\" data-dictid=\"e684325d851692777196af9e64013b\">Preventive</span> Therapy) - Rifapentine + Isoniazid Daily for 3  months</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<ul>\n\t<li>\n\t<p>Close household contacts of a patient with <strong>active tuberculosis</strong> are at <strong>high risk</strong> of developing TB, especially elderly and <span class=\"customMeta\" data-dictid=\"a3cc9f976916927771895692a1a8a0\">immunocompromised</span> individuals.</p>\n\t</li>\n\t<li>\n\t<p><strong>TB <span class=\"customMeta\" data-dictid=\"e684325d851692777196af9e64013b\">Preventive</span> Therapy (TPT)</strong> is recommended for these contacts after ruling out active disease.</p>\n\t</li>\n\t<li>\n\t<p><strong>Short-course regimens</strong> such as <strong>weekly Rifapentine + Isoniazid for 3 months (3HP)</strong> are <strong>WHO-endorsed</strong>, effective, and improve compliance.</p>\n\t</li>\n\t<li>\n\t<p>Particularly beneficial in <strong>resource-limited and high-burden settings</strong> due to shorter duration and fewer side effects.</p>\n\t</li>\n</ul>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"225\" src=\"https://image.prepladder.com/content/JDfBgjz1fn3oKlvurGzP1734267125.png\" width=\"500\" /></p>\n\n<p> </p>\n\n<p><strong>TB <span class=\"customMeta\" data-dictid=\"e684325d851692777196af9e64013b\">Preventive</span> Therapy (TPT) Options</strong></p>\n\n<table>\n\t<thead>\n\t\t<tr>\n\t\t\t<th><strong>Regimen</strong></th>\n\t\t\t<th><strong>Drugs Used</strong></th>\n\t\t\t<th><strong>Duration</strong></th>\n\t\t\t<th><strong>Target Groups</strong></th>\n\t\t\t<th><strong>Notes</strong></th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>3HP</strong></td>\n\t\t\t<td>Isoniazid + Rifapentine (weekly)</td>\n\t\t\t<td>3 months</td>\n\t\t\t<td>Adults and children >2 years, PLHIV, household contacts</td>\n\t\t\t<td>WHO-recommended; shorter duration improves adherence</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>6H</strong></td>\n\t\t\t<td>Isoniazid daily</td>\n\t\t\t<td>6 months</td>\n\t\t\t<td>All age groups, including children and PLHIV</td>\n\t\t\t<td>Traditional regimen; effective but lower <span class=\"customMeta\" data-dictid=\"5f8b7d103016927771806be7e4190b\">adherence</span> due to long duration</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>3HR</strong></td>\n\t\t\t<td>Isoniazid + Rifampicin daily</td>\n\t\t\t<td>3 months</td>\n\t\t\t<td>Children <15 years, PLHIV, household contacts</td>\n\t\t\t<td>WHO-recommended; safe for children</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>4R</strong></td>\n\t\t\t<td>Rifampicin daily</td>\n\t\t\t<td>4 months</td>\n\t\t\t<td>Individuals intolerant to INH, or where INH resistance is suspected</td>\n\t\t\t<td>Alternative <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> when INH is contraindicated</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p><strong>Isoniazid (600 mg OD) for 6 months (Option A):</strong><br />\nCorrect <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> (6H) but longer duration and more hepatotoxicity; 3HP is preferred.</p>\n\n<p> </p>\n\n<p><strong>Pyrizinamide (800 mg OD) for 3 months (Option C):</strong><br />\nIncorrect. <strong>Pyrazinamide is not used in TPT</strong> due to significant <span class=\"customMeta\" data-dictid=\"cbc7c810ce1692777188e6eaf3eba2\">hepatotoxicity</span> and lack of <span class=\"customMeta\" data-dictid=\"e684325d851692777196af9e64013b\">preventive</span> <span class=\"customMeta\" data-dictid=\"7f80be61231692777187391e91e867\">efficacy</span> when used alone.</p>\n\n<p> </p>\n\n<p><strong>Rifampicin (1500 mg OD) for 9 months (Option D):</strong><br />\nIncorrect. <strong>9 months of Rifampicin monotherapy</strong> is not a standard TPT regimen; usual Rifampicin-only TPT is <strong>4 months (4R)</strong>.</p>\n\n<p><br />\n </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/JDfBgjz1fn3oKlvurGzP1734267125.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/VgT2JkOB20jhJRVlAHHf1747247946.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/3r5YnTlXqP2yhXRPSkBl1747248002.mp3"
    },
    {
      "text": "A 25 year old woman, who is 18 weeks pregnant, is diagnosed with MDR-TB. She comes to you for advice on how to proceed with her pregnancy and treatment.\n\nWhat is the most appropriate management plan for this patient?",
      "choices": [
        {
          "id": 0,
          "text": "Start the Shorter oral Bedaquiline regimen immediately and continue the pregnancy."
        },
        {
          "id": 1,
          "text": "Advise Medical Termination of Pregnancy (MTP) and if done, start the Shorter oral Bedaquiline regimen."
        },
        {
          "id": 2,
          "text": "Start the Longer oral Bedaquiline regimen immediately and continue the pregnancy."
        },
        {
          "id": 3,
          "text": "Continue the pregnancy without initiating any TB treatment until the second trimester."
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) Advise Medical <span class=\"customMeta\" data-dictid=\"a35c217ec416927772009a7f3b20f4\">Termination</span> of Pregnancy (MTP) and if done, start the Shorter oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> regimen. </strong></p>\n\n<p> </p>\n\n<p><strong>Explanation: </strong></p>\n\n<p>The guidelines suggest advising <span class=\"customMeta\" data-dictid=\"eb06d1383216927771938c9eadb451\">MTP</span> for pregnant mothers who are less than 20 weeks pregnant ( due to significant risk to both mother & fetus) and, if <span class=\"customMeta\" data-dictid=\"eb06d1383216927771938c9eadb451\">MTP</span> is performed, the Shorter oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> should be given.</p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"357\" src=\"https://image.prepladder.com/content/ziLK59wxxFfPjP5zcluw1734266925.png\" width=\"500\" /></p>\n\n<p> </p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"243\" src=\"https://image.prepladder.com/content/8BsEUSC4NL6uKeEYl6KT1734266990.png\" width=\"500\" /></p>\n\n<ul>\n\t<li>Starting the Shorter oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> and continuing the pregnancy is not advised for a woman who is less than 20 weeks pregnant according to the guidelines given by MoHFW, Govt. of India. <strong>(Option A)</strong></li>\n\t<li>The Longer oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> is suggested for those who are more than 20 weeks pregnant and less than 32 weeks if <span class=\"customMeta\" data-dictid=\"eb06d1383216927771938c9eadb451\">MTP</span> is declined. This patient is only 18 weeks pregnant. <strong>(Option C)</strong></li>\n\t<li>Delaying TB treatment is not appropriate due to the risk of disease <span class=\"customMeta\" data-dictid=\"3c305b384216927771969ca4166493\">progression</span> and harm to both mother and fetus. <strong>(Option D)</strong></li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/ziLK59wxxFfPjP5zcluw1734266925.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/FKMeXcKoNow2hlob0jCW1747247111.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/I2TEYROK8ofaoOOuSZsP1747247206.mp3"
    },
    {
      "text": "Which of the following is false regarding the BPaL regimen used in the treatment of tuberculosis?",
      "choices": [
        {
          "id": 0,
          "text": "It was first studied clinically in the Nix-TB trial conducted by WHO"
        },
        {
          "id": 1,
          "text": "It can be used in patients with XDR-TB"
        },
        {
          "id": 2,
          "text": "It is used to treat MDR-TB patients who are unresponsive to treatment"
        },
        {
          "id": 3,
          "text": "It is used only in Rifampicin-resistant TB"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) It is used only in Rifampicin-resistant TB</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong> The BPaL <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> consists of Bedaquiline, Pretonamid and Linezolid.</p>\n\n<ul>\n\t<li>It was first studied clinically in the <span class=\"customMeta\" data-dictid=\"5835a765751692777195c32ef7fbec\">Phase 3</span> Nix-TB Trial conducted by WHO <strong>(Option A)</strong>.</li>\n\t<li>Nix-TB participants with XDR-TB <strong>(Option B)</strong> and treatment-intolerant or nonresponsive MDR-TB <strong>(Option C)</strong> were enrolled for treatment with the BPaL regimen.</li>\n</ul>\n\n<p>For rifampicin-only resistant cases, the shorter oral bedaquiline-containing <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> is used <strong>(Option D)</strong>.</p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/rwudQZiGIwues1Grjh2K1747247368.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/jqP7BNhwlOQ5Sfs85HHN1747423629.mp3"
    },
    {
      "text": "A 30 year old female came with complaints of evening rise of temperature, night sweats, cough and blood in sputum for the past 5 weeks. The doctor suspects TB and orders Sputum AFB, CBNAAT, and chest X-ray for the patient. All of the tests come out positive confirming her diagnosis of TB. The CBNAAT shows she is resistant to rifampicin but sensitive to isoniazid on first-line LPA.\n\nWhich of the following would be the most appropriate treatment regimen for her?",
      "choices": [
        {
          "id": 0,
          "text": "18 months:BDQC₂L₂ (Bdq-Bedaquiline, C-Cycloserine, C-Clofazimine, L-Linezolid, L-Levofloxacin)."
        },
        {
          "id": 1,
          "text": "4-6 months: CHOOBZEEt (Z-Pyrazinamide, E-Ethambutol, E-Ethionamide, C-Clofazimine, H-high dose Isoniazid, O-Levofloxacin, B-bedaquiline).·\n\n5 months: COZE (Z-Pyrazinamide, E-Ethambutol, O-Levofloxacin, C-Clofazimine)."
        },
        {
          "id": 2,
          "text": "2 months : HRZE (H-Isoniazide, R- Rifampicin, Z-Pyrazinamide, E-Ethambutol)\n\n4 months: HRE (H-Isoniazide, R- Rifampicin, E-Ethambutol)"
        },
        {
          "id": 3,
          "text": "6 months: ZERO (Z-Pyrazinamide, E-Ethambutol, R-Rifampicin, O-Levofloxacin)."
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) 4-6 months: CHOBZEEt (Z-Pyrazinamide, E-Ethambutol, E-Ethionamide, C-Clofazimine, H-high dose Isoniazid, O-Levofloxacin, B-bedaquiline); 5 months: COZE (Z-Pyrazinamide, E-Ethambutol, O-Levofloxacin, C-Clofazimine).</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation: </strong></p>\n\n<p>This patient is <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">Rifampicin</span> resistant and <span class=\"customMeta\" data-dictid=\"c2bea3e6d316927771904c30803e44\">INH</span> sensitive. Hence she should be given the Shorter oral Bedaquiline-containing regimen.</p>\n\n<p>The Shorter oral Bedaquiline-containing <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> is as follows:</p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:NaN\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>4-6 months of CHOBZEEt </strong></p>\n\n\t\t\t<p><strong>(Intensive phase)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Upto 5 months of COZE (continuation phase)</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Z - </strong>Pyrazinamide</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Z - </strong>Pyrazinamide</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>E - </strong>Ethambutol</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>E - </strong>Ethambutol</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>E -</strong> Ethionamide</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>O - </strong>Levofloxacin</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>C - </strong>Clofazimine</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>C - </strong>Clofazimine</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>H - </strong>high dose Isoniazid</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\"> </td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>O - </strong>Levofloxacin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\"> </td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>B - </strong>bedaquiline</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\"> </td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p><strong>18 months</strong> BDQC₂L₂ (Bdq-Bedaquiline, C-Cycloserine, C-Clofazimine, L-Linezolid, L-Levofloxacin).</p>\n\n<ul>\n\t<li>This refers to the Longer Oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> Containing Regimen.</li>\n\t<li>It is typically given to those TB patients who are resistant to both <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">Rifampicin</span> as well as <span class=\"customMeta\" data-dictid=\"c2bea3e6d316927771904c30803e44\">INH</span> & any <span class=\"customMeta\" data-dictid=\"f4975edd0b1692777203b54cf45c2d\">Fluoroquinolone</span> resistant. <strong>(Option A)</strong></li>\n</ul>\n\n<p><br />\n </p>\n\n<p><strong>2 months</strong>: HRZE (H-Isoniazide, R- Rifampicin, Z-Pyrazinamide, E-Ethambutol)</p>\n\n<p><strong>4 months:</strong> HRE (H-Isoniazide, R- Rifampicin, E-Ethambutol)</p>\n\n<ul>\n\t<li>This <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> is used for treating drug-sensitive TB cases. <strong>(Option B)</strong></li>\n</ul>\n\n<p> </p>\n\n<p><strong>6 months:</strong> <span class=\"customMeta\" data-dictid=\"116e588c7b1692777202c7f3040428\">ZERO</span> (Z-Pyrazinamide, E-Ethambutol, R-Rifampicin, O-Levofloxacin).</p>\n\n<ul>\n\t<li>This <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> is given for isoniazid-resistant cases & <span class=\"customMeta\" data-dictid=\"9ba1f027f01692777196f9b10e8446\">Poly</span> <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">Drug-resistant</span> (Other than <span class=\"customMeta\" data-dictid=\"5d8c24b3cb16927771909a5195d7f8\">Isoniazid</span> and Rifampicin) cases. <strong>(Option C)</strong></li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/MubLxCeoXFWyMpULc2h21747247519.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/aBfhSsxL5yql7mk0r2RZ1747423555.mp3"
    },
    {
      "text": "Which of the following statements is true regarding global initiative to control TB ?",
      "choices": [
        {
          "id": 0,
          "text": "To eliminate TB by 2050 under the End TB initiative."
        },
        {
          "id": 1,
          "text": "To reduce mortality of TB by 80% under Sustainable Development Goals"
        },
        {
          "id": 2,
          "text": "To reduce mortality & incidence of TB by 90% under the Stop TB initiative"
        },
        {
          "id": 3,
          "text": "To reduce incidence of TB by 80% under Sustainable Development Goals"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) To reduce <span class=\"customMeta\" data-dictid=\"17cd3771bb1692777190950c142dbe\">incidence</span> of TB by 80% under Sustainable Development Goals</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>SUSTAINABLE DEVELOPMENT GOAL (SDG) TO CONTROL TB</strong></p>\n\n<ul>\n\t<li>Aim: To eliminate TB by 2030.</li>\n\t<li>Target: Set by WHO\n\t<ul>\n\t\t<li>To reduce mortality of TB by 90% <strong>(Option B)</strong>.</li>\n\t\t<li>To reduce <span class=\"customMeta\" data-dictid=\"17cd3771bb1692777190950c142dbe\">incidence</span> of TB by 80% <strong>(Option D)</strong>.</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Global targets under SDG:</strong></p>\n\n<ul>\n\t<li>To reach 90% of all people with TB.</li>\n\t<li>To reach 90% of all key populations (Slum dwellers, prisoners, difficult to reach, occupational exposures-silicosis).</li>\n\t<li>To achieve 90% treatment.</li>\n</ul>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"291\" src=\"https://image.prepladder.com/content/oMBDyY1kOrFaIojsrBjw1734265492.png\" width=\"500\" /></p>\n\n<p><strong>END TB </strong></p>\n\n<ul>\n\t<li>Launched by WHO in 2015.</li>\n\t<li>Frameline: 2015 - 2035</li>\n\t<li>Aim: Eliminate TB by 2035<strong> (Option A)</strong></li>\n\t<li>Target: 95-90-0\n\t<ul>\n\t\t<li>Reduce mortality of TB by 95%</li>\n\t\t<li>Reduce <span class=\"customMeta\" data-dictid=\"17cd3771bb1692777190950c142dbe\">incidence</span> of TB by 90%</li>\n\t\t<li>Zero out of pocket expenditure - Government should look after the treatment.</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p> </p>\n\n<p><strong>STOP TB</strong></p>\n\n<ul>\n\t<li>It was in <span class=\"customMeta\" data-dictid=\"3c0c325f4216927771819e5d0eb581\">alignment</span> with Millennium development goals.</li>\n\t<li>Target: To reduce mortality & <span class=\"customMeta\" data-dictid=\"17cd3771bb1692777190950c142dbe\">incidence</span> of TB by 50% <strong>(Option C)</strong> And eliminate TB by 2050.</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/oMBDyY1kOrFaIojsrBjw1734265492.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/5QC1aVvGPWuBuzISSKnd1743279221.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/IdttBJXVqJ8mFTLUbO3l1743279291.mp3"
    },
    {
      "text": "A 45 year old woman presents to a Community Health Center (CHC) with a persistent cough, fever, and night sweats for the past three weeks. She has significant weight loss and a known history of contact with a TB patient. The clinician suspects TB and aims to confirm the diagnosis. According to NTEP guidelines, which of the following diagnostic modalities is not typically used for the initial diagnosis of TB?",
      "choices": [
        {
          "id": 0,
          "text": "Sputum smear microscopy"
        },
        {
          "id": 1,
          "text": "Chest X-ray"
        },
        {
          "id": 2,
          "text": "F/S Line Probe Assay"
        },
        {
          "id": 3,
          "text": "TruNAAT/CBNAAT"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) F/S Line <span class=\"customMeta\" data-dictid=\"175eb86b5f16927771964d5ced6bf3\">Probe</span> Assay</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The F/S Line <span class=\"customMeta\" data-dictid=\"175eb86b5f16927771964d5ced6bf3\">Probe</span> <span class=\"customMeta\" data-dictid=\"fc026ff6d81692777182835f6de6df\">Assay</span> is <strong>not typically used for the initial diagnosis of TB according to NTEP guidelines.</strong> This test is generally used <strong>for detecting specific drug resistances</strong> (like <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">rifampicin</span> and isoniazid) in previously confirmed TB cases and not for the primary diagnosis.</p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:648px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Diagnostic Modality</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Description</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Usage</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Sputum <span class=\"customMeta\" data-dictid=\"6777533153169277719804fcbbf2d1\">Smear</span> Microscopy</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Microscopic examination of <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> samples to detect <span class=\"customMeta\" data-dictid=\"440f2b916316927771808b8ad44a64\">acid-fast</span> <span class=\"customMeta\" data-dictid=\"fe0005a48b1692777182143f69e1d5\">bacilli</span> (AFB).</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used for initial screening and diagnosis, especially in resource-limited settings.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Chest X-ray</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Imaging done to identify abnormalities suggestive of TB.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used to support diagnosis when clinical suspicion is high; not <span class=\"customMeta\" data-dictid=\"32b854324a1692777185c6c79fdc99\">definitive</span> for TB diagnosis.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>TruNAAT/CBNAAT</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Molecular tests that detect Mycobacterial DNA and <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">rifampicin</span> resistance.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Recommended for initial diagnosis due to high sensitivity and specificity; rapid results.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Line <span class=\"customMeta\" data-dictid=\"175eb86b5f16927771964d5ced6bf3\">Probe</span> <span class=\"customMeta\" data-dictid=\"fc026ff6d81692777182835f6de6df\">Assay</span> (LPA)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Molecular test to detect specific genetic mutations associated with <span class=\"customMeta\" data-dictid=\"36f0ccd0621692777186c1c3cecf48\">drug resistance</span> (e.g., rifampicin, isoniazid).</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used for detecting <span class=\"customMeta\" data-dictid=\"36f0ccd0621692777186c1c3cecf48\">drug resistance</span> in confirmed TB cases, not for initial diagnosis.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Tuberculin Skin Test (TST)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>A skin test to measure <span class=\"customMeta\" data-dictid=\"dc6add5cf91692777189b30a6bae38\">immune response</span> to <span class=\"customMeta\" data-dictid=\"6a367ebd0c169277719091155a5b0f\">injected</span> <span class=\"customMeta\" data-dictid=\"0fe92012341692777201bab3db39b1\">tuberculin</span> protein.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Primarily used for screening <span class=\"customMeta\" data-dictid=\"cec2565ecd1692777191eed58869b2\">latent</span> TB infection; not specific for active TB diagnosis.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Interferon-Gamma Release Assays (IGRAs)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Blood <span class=\"customMeta\" data-dictid=\"0ac01cc0c31692777185cae5f28175\">cytokine</span> analysis test that measures <span class=\"customMeta\" data-dictid=\"dc6add5cf91692777189b30a6bae38\">immune response</span> to TB antigens.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used for detecting <span class=\"customMeta\" data-dictid=\"cec2565ecd1692777191eed58869b2\">latent</span> TB infection</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Sputum Culture</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Growing <span class=\"customMeta\" data-dictid=\"46f768d2e41692777193d69cbc7eec\">Mycobacteria</span> from <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> samples to confirm TB and test for drug susceptibility.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Gold standard for TB diagnosis; takes several weeks to obtain results.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug <span class=\"customMeta\" data-dictid=\"6ced8252211692777199ab0cc3f2bb\">Susceptibility</span> Testing (DST)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Testing TB bacteria from patient samples to determine resistance to TB drugs.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used to guide treatment by identifying <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">drug-resistant</span> strains in confirmed TB cases.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/brpzbayb1LbiWNGIUzO01747246295.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/JvBDmQZhFvdT2KH91BrH1747423486.mp3"
    },
    {
      "text": "A 50 year old man diagnosed with TB has undergone drug susceptibility testing (DST). The results show that he is resistant to both isoniazid and rifampicin but susceptible to all fluoroquinolones and second-line injectable drugs. According to the classification based on drug resistance in the NTEP guidelines, how should this patient's case be categorized?",
      "choices": [
        {
          "id": 0,
          "text": "Monoresistant TB"
        },
        {
          "id": 1,
          "text": "Polydrug-resistant TB"
        },
        {
          "id": 2,
          "text": "Multidrug-resistant TB (MDR-TB)"
        },
        {
          "id": 3,
          "text": "Extensively drug-resistant TB (XDR-TB)"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Multidrug-resistant TB (MDR-TB)</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The patient's case should be categorized as <strong>Multidrug-resistant TB (MDR-TB) because he is resistant to both <span class=\"customMeta\" data-dictid=\"5d8c24b3cb16927771909a5195d7f8\">isoniazid</span> (H) and <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">rifampicin</span> (R)</strong>, which defines MDR-TB. The <span class=\"customMeta\" data-dictid=\"dda6ab11271692777184264b752d39\">classification</span> is based on the resistance to these two key first-line anti-TB drugs.</p>\n\n<p><strong>Classification of TB Patients Based on Drug Testing</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:634px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Category</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Description</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug sensitive TB</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Patients are sensitive to 4 TB drugs: R,H,Z,E (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol).</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Mono-resistant (MR) (Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistant to one 1st line anti-TB drug only.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>H-Mono-resistant (H-MR)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistant to <span class=\"customMeta\" data-dictid=\"5d8c24b3cb16927771909a5195d7f8\">Isoniazid</span> (H) only.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Rifampicin resistant (RR)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistant to <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">Rifampicin</span> (R) only.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Multi drug resistant (MDR) (Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistant to both <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">Rifampicin</span> (R) & <span class=\"customMeta\" data-dictid=\"5d8c24b3cb16927771909a5195d7f8\">Isoniazid</span> (H).</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Poly-Drug resistant (PDR) (Option B)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistant to 2 drugs other than <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">Rifampicin</span> (R) & <span class=\"customMeta\" data-dictid=\"5d8c24b3cb16927771909a5195d7f8\">Isoniazid</span> (H).</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Pre-Xtensive resistant (pre-XDR)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Any <span class=\"customMeta\" data-dictid=\"3c0021ebec1692777192f766374e40\">MDR</span> patient (H+R) resistant to any fluoroquinolone.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Extensive resistant (XDR) (Option D)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Any <span class=\"customMeta\" data-dictid=\"3c0021ebec1692777192f766374e40\">MDR</span> patient (H+R) resistant to any <span class=\"customMeta\" data-dictid=\"f4975edd0b1692777203b54cf45c2d\">fluoroquinolone</span> and Group 4 drugs (Bedaquiline, Linezolid, Levo/Moxifloxacin).</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/7HvsAeeiaDlUMN25kV5n1747246111.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/JJpxH86Erj8yYtqkALN11747246200.mp3"
    },
    {
      "text": "A 40 year old woman has been diagnosed with TB. Her medical records indicate she completed a full course of TB treatment and was declared cured two years ago. However, she is now presenting with symptoms of TB again and has a positive sputum test. According to the classification based on the history of previous TB treatment under the NTEP, how should this patient's case be categorized?",
      "choices": [
        {
          "id": 0,
          "text": "New case"
        },
        {
          "id": 1,
          "text": "Treatment after failure"
        },
        {
          "id": 2,
          "text": "Treatment after loss to follow-up"
        },
        {
          "id": 3,
          "text": "Recurrent TB case"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) <span class=\"customMeta\" data-dictid=\"c64e3a661b1692777197afc2ff7bca\">Recurrent</span> TB case</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>This patient's case should be categorized as a \"Recurrent TB case\" because she had previously completed a full course of TB treatment and was declared cured.</p>\n\n<p>According to the NTEP classification, a <span class=\"customMeta\" data-dictid=\"c64e3a661b1692777197afc2ff7bca\">recurrent</span> TB case includes patients who were previously treated for TB, declared cured or treatment completed, and are now diagnosed with a <span class=\"customMeta\" data-dictid=\"c64e3a661b1692777197afc2ff7bca\">recurrent</span> episode of TB.</p>\n\n<p> </p>\n\n<p><strong>Classification of TB Patients based on History of Treatment</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Category</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Description</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>New case (Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Newly diagnosed case and has never taken TB treatment before/taken treatment for <1 month duration.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Previously treated case</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Taken TB treatment earlier for >1 month.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Recurrent TB case</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>TB patient declared cured or treatment complete, presents again as a microbiologically confirmed TB case.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Treatment after failure (Option B)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>TB patient who had been treated for TB & presents as a failure at the most recent course of treatment or is positive even at 5 months of treatment.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Treatment after loss to follow up (Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>A TB patient who received treatment for >1 month & registered as loss to follow up, is presenting again as a microbiologically positive TB case.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Other previously treated patients</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Earlier treatment is not known or not documented.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Transferred in</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Treatment starts at one TB unit, then the patient is transferred to another TB unit.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Cure</strong>: Treatment is complete + <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> negative report at the end of the treatment.<br />\n<strong>Treatment complete:</strong> Treatment is complete + <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> report is not available</p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/QTyXoAt9sDwLjX4I5GYV1747164066.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/SJq8iZ7kOdu1tr5DMh7V1747164158.mp3"
    },
    {
      "text": "A 35 year old man visits the clinic with a persistent cough and fever lasting for more than 2 weeks. He also reports experiencing night sweats and significant weight loss over the past month. Sputum smear tests or radiological tests are not yet done. According to the new terminologies in NTEP, how should this patient's case be categorized?",
      "choices": [
        {
          "id": 0,
          "text": "Clinically diagnosed TB case"
        },
        {
          "id": 1,
          "text": "TB suspect"
        },
        {
          "id": 2,
          "text": "Sputum negative TB case"
        },
        {
          "id": 3,
          "text": "Presumptive TB case"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) Presumptive TB case</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li>The patient should be categorized as a \"<strong>Presumptive TB case</strong>\" according to NTEP's new terminologies as the patient is showing <strong>cough, fever or <span class=\"customMeta\" data-dictid=\"a696a8e86016927771939c84736fbb\">night sweats</span> & apparent loss in weight for more than 2 weeks</strong>.</li>\n\t<li>The term <strong>Presumptive TB case</strong> is used in place of <strong>TB suspect (Option B)</strong> and refers to individuals who show symptoms suggestive of TB but have not yet been confirmed with a diagnosis.</li>\n\t<li>This term is crucial for early identification and screening of TB cases to initiate timely diagnosis and treatment.</li>\n\t<li>The new NTEP changes in terminologies are as follows:</li>\n</ul>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Category</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Description</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Criteria/Features</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Presumptive TB Case</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li><strong>Used in place of TB suspect</strong>.</li>\n\t\t\t\t<li>Individuals showing symptoms suggestive of TB but not yet confirmed.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Cough, Fever, <span class=\"customMeta\" data-dictid=\"a696a8e86016927771939c84736fbb\">Night sweats</span> +- Weight loss > 2 weeks</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Clinically Diagnosed TB Case</strong></p>\n\n\t\t\t<p><strong>(Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Sputum negative but with high clinical suspicion of TB.</li>\n\t\t\t\t<li><strong>Used in place of <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">Sputum</span> negative TB case. (Option C)</strong></li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Persistent symptoms despite negative <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> smear</li>\n\t\t\t\t<li>High clinical suspicion based on symptoms, radiological and <span class=\"customMeta\" data-dictid=\"1e9c8202241692777189dbac6cc062\">histological</span> features</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Bacteriologically Confirmed TB Case</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Biological <span class=\"customMeta\" data-dictid=\"c02ad9ae0f1692777198d76afc93c4\">specimen</span> is positive for <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> AFB and/or CBNAAT.</li>\n\t\t\t\t<li><strong>Used in place of <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">Sputum</span> positive TB case.</strong></li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Positive <span class=\"customMeta\" data-dictid=\"5353537f861692777199e48431cd88\">sputum</span> <span class=\"customMeta\" data-dictid=\"6777533153169277719804fcbbf2d1\">smear</span> for AFB</li>\n\t\t\t\t<li>Positive CBNAAT test confirming the presence of TB bacteria</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/ZrMmr2tlpQ4RTA6ihgbT1747245726.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/Gk9368s76QdJEeeMILkB1747246016.mp3"
    },
    {
      "text": "Select the correct option for a treatment protocol according to NTEP which does not have a separate Intensive and Continuation phase.\n\na. Drug-sensitive TB\nb. H mono/poly drug-resistant TB\nc. Shorter oral bedaquiline regimen\nd. Longer M/XDR-TB regimen",
      "choices": [
        {
          "id": 0,
          "text": "b, c and d"
        },
        {
          "id": 1,
          "text": "b and d"
        },
        {
          "id": 2,
          "text": "a, c and d"
        },
        {
          "id": 3,
          "text": "b and c"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) b and d</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The treatment protocol for H mono/poly <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">drug-resistant</span> TB and the longer M/XDR-TB <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> under NTEP <strong>does not have a separate <span class=\"customMeta\" data-dictid=\"901bf573f216927771905f0abedca2\">Intensive</span> and Continuation phase.</strong> These regimens are continuous and do not distinguish between the two phases, unlike the drug-sensitive TB and shorter oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">bedaquiline</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> which have <span class=\"customMeta\" data-dictid=\"901bf573f216927771905f0abedca2\">Intensive</span> and Continuation Phase.</p>\n\n<p> </p>\n\n<p><strong>Treatment Regimens for TB according to NTEP (Revised 2022)</strong></p>\n\n<p> </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Regimen Class</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Intensive Phase</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Continuation Phase</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Notes</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug-sensitive TB</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2 months: H+R+Z+E</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4 months: H+R+E</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">-</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>H mono/poly <span class=\"customMeta\" data-dictid=\"d4c88fcae71692777186aa1c32423a\">drug-resistant</span> TB</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>6 months: Lfx+R+E, Z</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>No separate phase</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">-</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Shorter oral <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">bedaquiline</span> <span class=\"customMeta\" data-dictid=\"988bd8e7c71692777197b9f1d5d5ca\">regimen</span> (Shorter MDR-TB</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4-6 months: Bdq+Lfx+Cfz+Z+E+H(high dose)+Eto.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>5 months: Lfx+Cfz+Z+E</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Bdq to be given for 6 months.</p>\n\n\t\t\t<p>H to be given in high doses.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Longer M/XDR-TB regimen</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>18-20 months: Lfx+Bdq+Lzd+Cfz+Cs</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>No separate phase</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">-</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><br />\nNote:</p>\n\n<ul>\n\t<li>H - Isoniazid</li>\n\t<li>R - Rifampicin</li>\n\t<li>Bdq - Bedaquiline</li>\n\t<li>Lfx - Levofloxacin</li>\n\t<li>Cfz - Clofazimine</li>\n\t<li>Z - Pyrazinamide</li>\n\t<li>E - Ethambutol</li>\n\t<li>H (high dose) - High-dose Isoniazid</li>\n\t<li>Eto - Ethionamide</li>\n\t<li>Lzd - Linezolid</li>\n\t<li>Cs - Cycloserine</li>\n</ul>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/UCgLgRO3bRryW4Yvah9k1747245552.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/pckdZQyNNJDZlBpCyPnK1747423415.mp3"
    },
    {
      "text": "Match the following:\n\n\n\t\n\t\t\n\t\t\t\n\t\t\ta. Active case Detection\n\t\t\t\n\t\t\t\n\t\t\ti) Hospital reports are used for case detection\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\tb. Intensified case finding\n\t\t\t\n\t\t\t\n\t\t\tii) ASHA workers receive incentive of Rs. 500 for finding a presumptive case\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\tc. Community based screening\n\t\t\t\n\t\t\t\n\t\t\tiii) Initiates screening of TB symptoms\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\td. Passive case detection\n\t\t\t\n\t\t\t\n\t\t\tiv) ASHA workers collect details of risk factors of TB and diabetes.",
      "choices": [
        {
          "id": 0,
          "text": "a-ii, b-iii, c-iv, d-i"
        },
        {
          "id": 1,
          "text": "a-iii, b-ii, c-i, d-iv"
        },
        {
          "id": 2,
          "text": "a-iv, b-iii, c-ii, d-i"
        },
        {
          "id": 3,
          "text": "a-i, b-iii, c-ii, d-iv"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p> </p>\n\n<p><strong>Correct Answer: A) a-ii, b-iii, c-iv, d-i</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation: </strong></p>\n\n<p>Active case Detection:</p>\n\n<ul>\n\t<li>House-to-house search for TB cases in prisons, slums, and tribal areas.</li>\n\t<li>ASHA workers are involved.</li>\n\t<li>ASHA workers receive an <strong>incentive of Rs. 500 for finding a <span class=\"customMeta\" data-dictid=\"cced7d91ec169277719680ab298ccf\">presumptive</span> case.</strong></li>\n\t<li>Any member in the community helping in the identification of <span class=\"customMeta\" data-dictid=\"cced7d91ec169277719680ab298ccf\">presumptive</span> TB cases gets an incentive of Rs. 500.</li>\n</ul>\n\n<p> </p>\n\n<p>Intensified case finding:</p>\n\n<ul>\n\t<li>Provider initiated <strong>screening for TB symptoms</strong> in OPD.</li>\n\t<li>TB screening of patients presenting to health facilities with other comorbidities.</li>\n</ul>\n\n<p> </p>\n\n<p>Community based screening:</p>\n\n<ul>\n\t<li>ASHA workers fill a community based assessment checklist (CBAC) form, asking the <strong>risk factors for diabetes and other <span class=\"customMeta\" data-dictid=\"9996ef505516927771937fe4ef1222\">non</span> <span class=\"customMeta\" data-dictid=\"6f6ef8bf7c1692777184dfdf8cf45d\">communicable</span> diseases along with TB.</strong></li>\n\t<li>She gets Rs. 10 per <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> filled.</li>\n</ul>\n\n<p> </p>\n\n<p>Passive case detection:</p>\n\n<ul>\n\t<li>Passive surveillance from the<strong> hospital reports. </strong></li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/Ae5H9uwNs240GJOOdQaI1747248071.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/8xkP0u3OkJ2RM5vtZc341747423307.mp3"
    },
    {
      "text": "Which of the following is the main component of the JEET strategy to control TB ?",
      "choices": [
        {
          "id": 0,
          "text": "To increase the notification rates of TB by private practitioners."
        },
        {
          "id": 1,
          "text": "To open various testing centers for TB"
        },
        {
          "id": 2,
          "text": "Latest pharmaceutical innovation for early detection"
        },
        {
          "id": 3,
          "text": "Improved infrastructure for better isolation facilities to control TB"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct Answer: A) To increase the notification rates of TB by private practitioners.</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<div style=\"text-align:center\">\n<figure class=\"caption_element\" style=\"display:inline-block\"><img alt=\"\" data-author=\"NA\" data-hash=\"\" data-license=\"NA\" data-source=\"NA\" data-tags=\"\" height=\"148\" src=\"https://image.prepladder.com/content/RhOi9oVrcPGcmq25TRgo1734265957.png\" width=\"500\" />\n<figcaption>{{caption_text}}</figcaption>\n</figure>\n</div>\n\n<ul>\n\t<li>Indian organisations, Ministries, NGOs, and International Organizations work together to eliminate TB.</li>\n\t<li>The main reason for incomplete TB elimination: Non-notification by private practitioners.</li>\n\t<li>Strategy: To increase private practitioners' notification rates of TB.</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/RhOi9oVrcPGcmq25TRgo1734265957.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/98AG4aBIEwNfUqOpcIaC1743279881.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/jcr6FSYyhOcZ8bROBKNA1743280003.mp3"
    },
    {
      "text": "Which of the following is not the strategy of NTEP ?",
      "choices": [
        {
          "id": 0,
          "text": "CB-NAAT done for Anyone with cough > 2 weeks"
        },
        {
          "id": 1,
          "text": "TRUENAT gives result of rifampicin resistance within 1 hour"
        },
        {
          "id": 2,
          "text": "Shorter & Longer oral MDR/XDR regimens are introduced."
        },
        {
          "id": 3,
          "text": "Aim is to Prevent, Detect and Treat"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) Aim is to Prevent, Detect and Treat</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>National Strategic Plan for TB <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">Elimination</span> :</p>\n\n<ul>\n\t<li><strong>Detect-Treat-Prevent</strong>.</li>\n\t<li>Universalization of CB-NAAT - Anyone with <span class=\"customMeta\" data-dictid=\"8f02e74e821692777185a0c005c508\">cough</span> > 2 weeks (presumptive TB case): CB-NAAT is done at baseline.</li>\n\t<li>TRUENAT developed by ICMR - Indian version of CB-NAAT (gives result of <span class=\"customMeta\" data-dictid=\"6cd890fc7416927771978562618db8\">rifampicin</span> resistance within 1 hour).</li>\n\t<li>New drug regimens - <span class=\"customMeta\" data-dictid=\"d0a85225e8169277718252304cfc4b\">Bedaquiline</span> & Delamanid are introduced.</li>\n\t<li>Shorter & Longer oral MDR/XDR regimens are introduced.</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/SvuRdLMjqTl2iSjAPnao1743279723.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/5hGhM1Yg36a6vtfZxANa1743279826.mp3"
    },
    {
      "text": "Which of the following statements is true?",
      "choices": [
        {
          "id": 0,
          "text": "To eliminate TB by 2025 under National Tuberculosis Elimination Programme"
        },
        {
          "id": 1,
          "text": "Eliminate malaria throughout the entire country by 2050 under National Framework for Malaria Elimination in India"
        },
        {
          "id": 2,
          "text": "To achieve zero new infection and AIDS-related deaths by 2035"
        },
        {
          "id": 3,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct Answer: A) To eliminate TB by 2025 under National <span class=\"customMeta\" data-dictid=\"8d98ce2d3616927772013bfc3e0528\">Tuberculosis</span> <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">Elimination</span> Program</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>Targets of NTEP:</p>\n\n<ul>\n\t<li>Elimination of TB by 2025</li>\n\t<li>To reduce mortality of TB by 90%</li>\n\t<li>To reduce <span class=\"customMeta\" data-dictid=\"17cd3771bb1692777190950c142dbe\">incidence</span> of TB by 80%</li>\n\t<li>Zero catastrophic cost for treatment</li>\n</ul>\n\n<p><strong>The 2035 targets are a 95% reduction in TB deaths and a 90% reduction in TB incidence.</strong></p>\n\n<p>Vision of NTEP:</p>\n\n<ul>\n\t<li>TB free India</li>\n\t<li>0 death, 0 disease, 0 poverty</li>\n</ul>\n\n<p> </p>\n\n<p>Malaria <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">elimination</span> is aimed by 2030 under the National Framework for <span class=\"customMeta\" data-dictid=\"8b4c650ddd1692777191286afbcd8a\">Malaria</span> <span class=\"customMeta\" data-dictid=\"86c65ffa40169277718763f4072c2f\">Elimination</span> in India. <strong>(Option B)</strong></p>\n\n<p> </p>\n\n<p>80% reduction in new <span class=\"customMeta\" data-dictid=\"fa9d83d3d41692777189a8b393dd60\">HIV</span> infections under the National AIDS Control Programme by 2024 <strong>(Option C)</strong></p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/CSZ5wIIpjh0Bm5icjeMX1743279524.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/Gk6t3WulByjSaZ9JmKpw1743279610.mp3"
    }
  ]
}